Mark Lingen to Survival Rate
This is a "connection" page, showing publications Mark Lingen has written about Survival Rate.
Connection Strength
0.076
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.028
-
Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
Score: 0.026
-
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
Score: 0.023